ProQR Therapeutics (PRQR) Return on Sales (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Return on Sales for 14 consecutive years, with 0.07% the latest figure, recorded in Q1 2026.

• Quarterly Return on Sales fell 4.0% year-over-year to 0.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.03% (down 2.0% YoY) and the FY2025 annual result came in at 0.03%, down 1.0% from the prior year.
• Return on Sales slipped to 0.07% in Q1 2026 per PRQR's latest filing, from 0.02% in the prior quarter.
• Over the last five years, Return on Sales for PRQR reached as high as 0.0% in Q2 2024 and fell as low as 0.28% in Q3 2022.
• A 5-year average of 0.07% and a median of 0.04% in 2025 frame the typical range for Return on Sales.
• The largest YoY upside for Return on Sales was 57 bps in 2022 against a maximum downside of 11 bps in 2022.
• Year by year, Return on Sales stood at 0.19% in 2022, then jumped by 89 bps to 0.02% in 2023, then climbed by 0 bps to 0.02% in 2024, then retreated by 4 bps to 0.02% in 2025, then tumbled by 207 bps to 0.07% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.07%, 0.02%, and 0.04% for Q1 2026, Q4 2025, and Q3 2025 respectively.